Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
CTKB - Cytek Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.13
DETAILS
HIGH:
$5.50
LOW:
$4.75
MEDIAN:
$5.12
CONSENSUS:
$5.13
UPSIDE:
27.93%
Stock News
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.09 per share a year ago.
Cytek Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.
Analysts Set Cytek Biosciences, Inc. (NASDAQ:CTKB) PT at $5.38
Cytek Biosciences, Inc. (NASDAQ: CTKB - Get Free Report) has been assigned an average recommendation of "Hold" from the six brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026.
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences (NASDAQ: CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen's 42nd annual healthcare conference. CEO and Chairman Wenbin Jiang and CFO William McCombe discussed the company's installed base growth, the increasing contribution of recurring revenue streams, and how management is thinking about
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025.
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026.
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Price Targets
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
$4.75
(was $4.04)
Stephens
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
$5.50
(was $4.07)
Morgan Stanley
Cytek Biosciences assumed with an Equal Weight at Morgan Stanley
$6.00
(was $5.33)
Morgan Stanley
Cytek Biosciences price target lowered to $8 from $8.25 at Piper Sandler
$8.00
(was $4.31)
Piper Sandler
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs
$5.25
(was $5.15)
Matthew Sykes
·
Goldman Sachs
Cytek Biosciences Inc (CTKB) PT Lowered to $8.50 at Piper Sandler
$8.50
(was $6.15)
Dave Westenberg
·
Piper Sandler
Cytek Biosciences price target raised to $16 from $12 at Piper Sandler
$16.00
(was $14.08)
David Westenberg
·
Piper Sandler
Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler
$12.00
(was $9.38)
David Westenberg
·
Piper Sandler